SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for…
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) — In a release issued under the same…
LONDON & NEW YORK–(BUSINESS WIRE)–Cazoo Group Ltd (NYSE: CZOO) (“Cazoo” or “the Company”), Europe’s leading…
Three Pilot Programs Will Shape How Electric Vehicles Can Help Power the Grid and Benefit…
The Military Spouse Homefront Heroes Hiring Program Provides Portable Career Opportunities in Mid- to High-Level…
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare…
Annual Meeting to be reconvened on May 18, 2022 MALVERN, Pa., May 05, 2022 (GLOBE…
Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time…
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active…
Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications…
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO) today announced…
– Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine…
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader…
EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,”…
On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients…
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — Cellectis S.A. (Euronext Growth: ALCLS – NASDAQ:…
Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a…
ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing…
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) — PacBio announced today that it will…